Vicore Pharma Holding AB (STU:6Y4) Marketable Securities : €30.43 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Vicore Pharma Holding AB Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vicore Pharma Holding AB's Marketable Securities for the quarter that ended in Mar. 2025 was €30.43 Mil.

Vicore Pharma Holding AB's annual Marketable Securities increased from Dec. 2022 (€0.45 Mil) to Dec. 2023 (€13.32 Mil) but then declined from Dec. 2023 (€13.32 Mil) to Dec. 2024 (€0.00 Mil).

Vicore Pharma Holding AB Marketable Securities Historical Data

The historical data trend for Vicore Pharma Holding AB's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vicore Pharma Holding AB Marketable Securities Chart

Vicore Pharma Holding AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Marketable Securities

Get a 7-Day Free Trial

6.88

7.50

0.45

13.32

Vicore Pharma Holding AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Marketable Securities	Get a 7-Day Free Trial															7.16	9.55	3.86	-	30.43

Vicore Pharma Holding AB Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Vicore Pharma Holding AB (STU:6Y4) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vicore Pharma Holding AB Marketable Securities Related Terms

Thank you for viewing the detailed overview of Vicore Pharma Holding AB's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Vicore Pharma Holding AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vicore Pharma Holding AB (STU:6Y4) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

VICO:Sweden 6Y4:Germany

Address

Kornhamnstorg 53, Stockholm, SWE, 111 27

Website

https://www.vicorepharma.com

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on severe lung diseases. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Its C21 is a small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2b development for IPF. The company also has an investigational medical device in clinical development, namely, Almee, which is a digital therapeutic leveraging cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis.

Vicore Pharma Holding AB Headlines

No Headlines